Global Academic Journal of Agriculture and Bio sciences

Available online at https://www.gajrc.com
DOI: https://doi.org/10.36348/gajab.2026.v08i03.001

OPEN ACCESS



ISSN:2706-8978 (P)
ISSN: 2707-2568 (O)

Review Article

The Pathogenic Continuum of Staphylococcus Aureus in the Axillary Region: From Superficial Dermatitis to Regional Lymphadenitis

Asst. Prof. Dr. Shler Ali Khorsheed[1]*
[1]Open Educational College, Department of Biology, Kirkuk, Iraq

***Corresponding Author**
Asst. Prof. Dr. Shler Ali Khorsheed
Open Educational College, Department of Biology, Kirkuk, Iraq

Article History
Received: 04.03.2026
Accepted: 29.04.2026
Published: 05.05.2026

Abstract: The physiological and microbial evolution of Staphylococcus aureus (S. aureus) from its localized, superficial dermatitis stage to being an invasive source of regional lymphadenitis occurs within the axillary region (i.e., depending on where the colonization occurs, can also apply to the inguinal region). The axilla has an environment characterized by high moisture, large amounts of apocrine secretions, and an abundant and dense lymphatic system, all conducive to being a primary reservoir for S. aureus colonization and subsequent infection. While early-stage dermatitis is characterized by localized epidermal inflammation and considerable barrier disruption, the transition from dermatitis to lymphadenitis signifies a severe systemic failure of the host's innate immunity. The transitions occurring along this continuum of pathogenesis are predicated on the increased expression of bacterial-specific virulence factors. This article addresses how Panton-Valentine leukocidin (PVL) and Alpha-hemolysin promote necrotic tissue destruction and immune escape. The review discusses the increased prevalence of Community-Acquired Methicillin-Resistant S. aureus (CA-MRSA) and the difficulty of managing CA-MRSA in terms of its ability to penetrate deep into tissues. In addition to reviewing the relationship between the axillary environment and bacterial adaptation, the review highlights that minor breaks in the skin can lead to deep-seated lymphatic disease. Therefore, the synthesis recommends that to effectively manage the transition from a localized infection to a serious infection, an integrated clinical approach is necessary that incorporates early dermatologic barrier replacement and targeted antibiotics. To help prevent localized axillary infections from advancing to serious regional complications, it is also important for physicians to understand the mechanisms that lead to this microbiological progression so they can implement early intervention and appropriate therapies to enhance patient outcomes.

Keywords: Staphylococcus Aureus. Axillary Region, Superficial Dermatitis, Regional Lymphadenitis, Pathogenic Continuum, Panton-Valentine Leukocidin (PVL).

INTRODUCTION

1. The Clinical and Ecological Dynamics of *S. aureus* in the Axillary Niche

The axillary niche is complex and continually challenged as an environmental niche by the clinical and ecological dynamics of Staphylococcus aureus (S. aureus), one of the most hazardous pathogens that can affect humans due to its exceptional ability to adapt genetically and to thrive in many different microbial environments found in humans, including the abovementioned location on/in the body. The

skin's natural "acid mantle" is greatly reduced in effectiveness because of these conditions relative to other sites on the surface of the body (i.e., arms and legs) [1, 2]. The development of S. aureus in the region often begins with dermatitis at the axilla, whereas dermatitis is defined as an inflammatory state that becomes worse because of mechanical trauma (e.g. trichotomy [shaving]), chemical irritation from cosmetics, and/or occlusional friction associated with intertrigo [3]. While commonly thought to be an irritation that is self-limited, new microbiological data suggests that this dermatitis is a significant "pathogenic entry point." During this early stage, S. aureus will frequently will switch from a planktonic growth phenotype to a biofilm phenotype that protects the S. aureus from topical antimicrobial agents and host surveillance [4]. A major change to the “Pathogenic Continuum” occurs when the skin's innate defense system fails. This can happen when keratinocytes (the cells in the skin) lose structural integrity or when the antimicrobial peptides (AMPs)—such as cathelicidins and beta-defensins—create a chemical barrier that is no longer intact [5]. Once the skin is compromised, Staphylococcus aureus (S. aureus) uses an arsenal of exoenzymes (e.g., hyaluronidase and proteases) to degrade the extracellular matrix, allowing S. aureus to migrate into the deeper dermis and eventually to the afferent lymphatic system [6]. The end result of this process is axillary lymphadenitis, which indicates that S. aureus has progressed from causing localized skin damage to invading the lymphatic system regionally. The increase in severity of localized skin damage (e.g., an abscess) associated with the presence of these virulent strains (e.g., community-acquired methicillin-resistant S. aureus [CA-MRSA]) is due in part to their ability to produce toxins that induce pyoptosis in the immune cells of the host [7]. Identifying the molecular connections between clinical stages of infection is critical not only in preventing chronic recurrence, but also in developing targeted methods to block entry of bacteria from the surface to deeper systems [8].

2. Clinical Pathogenesis and the Barrier-Breach Model

The transition from initial infection of the skin to deeper infections follows a specific pattern: First, S. aureus adheres to the skin's barrier using specialized proteins to attach to damaged skin [9]. Second, the presence of certain staphylococcal enzymes activates the immune response in the area, causing inflammatory cells (neutrophils) to attack, resulting in a rash or skin lesion [10]. Lastly, if local immune responses are inadequate to stop the invading bacteria, S. aureus utilizes its own enzymes to break down parts of the body surrounding its site of entry and gain access to the lymphatic circulatory system by any means necessary. The number of lymphatic vessels in the axilla (armpit) aids this process because there is a high density of lymphatics in this area [12].

3. Comparative Virulence and Toxin Profiles

One of the primary discoveries in the field of clinical microbiology is the change in virulence of bacteria as they are translocated throughout the body. Included in these findings are: Panton-Valentine leukocidin (PVL), which is commonly found in bacterial strains that cause lymphadenitis; PVL is a bi-component cytotoxin that causes leukocyte pore development; therefore, contributing to the liquefied necrosis and pus that are associated with typical nodal abscess; alpha-hemolysin (Hla) is heterogeneously produced by certain strains of bacteria that exhibit both stages of infection; Hla is necessary to disrupt the integrity of epithelium in the dermatitis phase of infection and to neutralize nodal macrophages during the phase of lymphadenitis; superantigens, refer to strains of the organisms that cause deep infections; these organisms also express toxic shock syndrome toxin-1 (TSST-1), which is an exogenously dimensional superantigen; therefore, TSST-1 allows for bypassing normal immune processing, resulting in massive cytokine release, thus resulting in systemic signs of illness such as fever and malaise.

4. Dynamics of Antimicrobial Resistance

Topical Resistance: Axillary dermatitis, a chronic condition of the armpits, is usually treated with a topical therapy. Since there has been increasing resistance to the mupA-encoded resistant topical agents such as Mupirocin and Fusidic acid, these agents are likely to become useless [17, 18].

Systemic Resistance (MRSA): Lymphadenitis in this region has also frequently been caused by CA-MRSA especially strains of USA300 [19]. The acquisition of mecA gene on the SCCmec type IV allows these strains of MRSA to be resistant to all the β-lactam drugs and more invasive therapies such as Vancomycin, Linezolid or Daptomycin are warranted [20].

5. Conclusion and Clinical Recommendations

The continuum from axillary dermatitis to lymphadenitis, shows that the skin can be a reservoir for invasive organisms. Dual-target treatment of a nodal infection will always involve systemic antibiotics targeting the nodes and antiseptic topical agent for axillary decolonisation and clearance of staphylococci on skin surface, such as a routine with chlorhexidine to remove this carriage [20, 21].

DISCUSSION

Describes in detail the multistep biologic pathway in which’s. Aureus will spread from a

cutaneous resident to a lymphatic intruder, in the distinct environment of the axilla. Because the high humidity and abundant nutrient content in the apocrine secretions within the axilla provides a less acidic environment, which compromised the normal skin barrier, the axilla can be an "incubator for perfect infection." [23]. It should also be mentioned that the progression from a localized cutaneous infection to regional lymphadenitis is not simply the result of proliferation, but rather an intricate invasion that relies on individual virulence factors [24].

Underlying this spread are the toxins Panton-Valentine leukocidin (PVL) and alpha-hemolysin. These, in essence, form a "molecular breaking crew"; PVL destroys phagocytes (white blood cells), and alpha-hemolysin breaks down cell to cell adhesion points within the skin barrier itself. Both toxins lead to tissue liquifaction, essentially breaking open the skin and allowing the pathogen to penetrate past the body's defenses. As soon as the basement membrane of the skin is breached, the extremely vascular network of axillary lymph vessels serves as an express route, carrying bacteria to regional lymph nodes rapidly [25].

This danger has been greatly amplified by the proliferation of CA-MRSA which are intrinsically designed to penetrate deeper and create higher levels of toxins [26]. It is also concluded that the optimal clinical approach is not just killing the bacteria but to both proactively restore barrier integrity (to limit entry in the first instance) while also targeting antimicrobials at toxin suppression. It is important to recognize the bacterial escalation, so as to manage initial axillary irritations that can otherwise result in major systemic lymphatic problems [26].

In sum, the pathogenesis of S. Aureus infection in the axilla is a complex process in which site of susceptibility meets a virulent organism. Anatomical weakness of the axilla, with its abundant moisture and access to the lymphatics, is the site of infection. An aggressiven synergistic attack by toxins such as PVL and alpha-hemolysin creates opportunity in the superficial infection, leading to invasive lymphadenitis by degrading host immune components and giving the bacteria an entry into the deep tissue [27].

It seems that the 'progression' that has been so difficult to halt can only be interrupted by reorientating the focus of treatment from purely reactive therapy to the proactive dual strategy of both killing the pathogen and preserving the integrity of the skin. Viewing the axilla as a focal high risk 'reservoir' can allow for a preemptive approach in the form of both reinstating the epidermal barrier and employing therapy that inhibits the exotoxins, hence, breaking the "pathogenic continuum" before it progresses from local skin irritation to life threatening systemic illness [28].

CONCLUSION

The pathogenesis of S aureus in the axilla involves an intricate relationship between anatomic predisposition and the bacterial "assault squad". This humid, nutrient rich, less acidic microenvironment of the axilla serves as a veritable incubators which debilitates skin barrier integrity and promote dominant bacterial colonization. In addition, the transformation from a shallow local break into invasive lymphadenitis is far from opportunistic; it is a choreographed event involving the actions of a team of "molecular breaking crew". Alpha-hemolysin and PVL serve as the leading crew members as these virulence factors can degrade junction proteins, render white blood cells defenseless, and clear the pathway to the abundant axillary lymph network. It will require new clinical intervention to tackle this "pathogenic continuum", moving from a more reactive antimicrobial therapy to a pro-active, "dual" therapy approach.

Eliminating pathogens: Employing appropriate antimicrobial treatment that not only eradicates bacteria but also inhibits the generation of toxins (essential for CA-MRSA).

Restoring barriers: Introduction of therapeutic agents at the earliest stage possible to repair skin structure and prevent invasion of pathogens into the systemic circulation.

REFERENCES

1. Dryden, M. S. (2009). Complicated skin and soft tissue infection: the epidemiology, relevance of HIV and therapy. *International Journal of Antimicrobial Agents*, 34(1), 14-17.
2. Grice, E. A., & Segre, J. A. (2011). The skin microbiome. *Nature Reviews Microbiology*, 9(4), 244-253.
3. Tong, S. Y., Davis, J. S., Eichenberger, E., Holland, T. L., & Fowler, V. G. (2015). Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. *Clinical Microbiology Reviews*, 28(3), 603-661.
4. Shler, A. K. (2024). Diagnosis of bacteria isolated from patients with cutaneous eczema by PCR technique at Azadi Hospital, Kirkuk, Iraq. *GSC Biological and Pharmaceutical Sciences*, 28(03), 240–247.
5. Miller, L. G., & Kaplan, S. L. (2009). Staphylococcus aureus: a community-acquired pathogen. *The Lancet Infectious Diseases*, 9(1), 22-30.

6. Bylander, A., et al. (2020). Alpha-hemolysin facilitates Staphylococcus aureus invasion and intracellular survival. *Frontiers in Cellular and Infection Microbiology*, 10, 25.
7. Gallo, R. L., & Hooper, L. V. (2012). Epithelial antimicrobial defence of the skin and intestine. *Nature Reviews Immunology*, 12(7), 503-516.
8. Lowy, F. D. (1998). Staphylococcus aureus infections. *New England Journal of Medicine*, 339(8), 520-532.
9. Otto, M. (2013). Staphylococcus aureus biofilms. *Microbiology Spectrum*, 1(4). doi: 10.1128/microbiolspec.VMBF-0012-2012.
10. Tam, K., & Torres, V. J. (2019). *Staphylococcus aureus* secreted toxins and extracellular enzymes. *Microbiology Spectrum*, 7(2). (
11. David, M. Z., & Daum, R. S. (2017). Community-associated Methicillin-Resistant *Staphylococcus aureus*: Epidemiology and clinical considerations. *Clinical Microbiology Reviews*, 30(1), 1–60.
12. Brandt, S. L., et al. (2018). Role of Panton-Valentine Leukocidin (PVL) in *Staphylococcus aureus* skin and soft tissue infections. *Toxins*, 10(10), 397.
13. Nakatsuji, T., & Gallo, R. L. (2012). Antimicrobial peptides: Old molecules with new ideas. *Journal of Investigative Dermatology*, 132(3), 887-895.
14. Shler, A. K. (2025). The frequency of Staphylococcus aureus in atopic dermatitiscases in Kirkuk City, Iraq. *Int J Biol Med Res*, 16(3): 8090-8094
15. Grice, E. A., & Segre, J. A. (2011). The skin microbiome. *Nature Reviews Microbiology*, 9(4), 244-
16. Kobayashi, S. D., et al. (2015). Pathogenesis of *Staphylococcus aureus* abscesses. *The American Journal of Pathology*, 185(6), 1518-1527.
17. Foster, T. J., Geoghegan, J. A., Ganesh, V. K., & Hook, M. (2014). Adhesion, invasion and evasion: the many roles of the surface proteins of Staphylococcus aureus. *Nature Reviews Microbiology*, 12(1), 49-62.
18. Kobayashi, S. D., Malachowa, N., & DeLeo, F. R. (2015). Pathogenesis of Staphylococcus aureus abscesses. *The American Journal of Pathology*, 185(6), 1518-1527.
19. Cho, S. H., et al. (2001). Characterization of Staphylococcus aureus isolates from patients with atopic dermatitis and healthy controls. *Applied and Environmental Microbiology*, 67(12), 5488-5494.
20. Powers, M. E., & Bubeck Wardenburg, J. (2014). Igniting the fire: Staphylococcus aureus virulence factors in the pathogenesis of sepsis. *Trends in Microbiology*, 22(1), 6-12.
21. Scallan, J. P., Huxley, V. H., & Korthuis, R. J. (2010). Lymphatic system physiology and law of the microcirculation. *Physiology*, 25(3), 144-153.
22. Boyle-Vavra, S., & Daum, R. S. (2007). Community-acquired methicillin-resistant Staphylococcus aureus: the role of Panton-Valentine leukocidin. *Laboratory Investigation*, 87(1), 3-9.
23. Lina, G., et al. (1999). Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. *Clinical Infectious Diseases*, 29(5), 1128-1132.
24. Berube, B. J., & Bubeck Wardenburg, J. (2013). Staphylococcus aureus α-toxin: nearly a century of intrigue. *Toxins*, 5(6), 1140-1166.
25. Talan, D. A., et al. (2011). Subgroup analysis of antibiotic treatment for skin abscesses. *Clinical Infectious Diseases*, 53(10), 1030-1031.
26. Patel, J. B., et al. (2009). Treatment of community-associated methicillin-resistant Staphylococcus aureus skin and soft tissue infections. *Clinical Infectious Diseases*, 48(Supplement 1), S1-S3.
27. Lauderdale, T. L., et al. (2008). Molecular epidemiology of community-associated meticillin-resistant Staphylococcus aureus in Taiwan. *Journal of Clinical Microbiology*, 46(12), 3989-3995.
28. Diep, B. A., et al. (2006). Complete genome sequence of USA300, the highly virulent community-associated methicillin-resistant Staphylococcus aureus strain. *The Lancet*, 367(9512), 731-739.
29. David, M. Z., & Daum, R. S. (2010). Community-associated methicillin-resistant Staphylococcus aureus: epidemiology and clinical consequences of an emerging epidemic. *Clinical Microbiology Reviews*, 23(3), 616-687.